Fostamatinib (TAK-079 / MND-379)
Chronic Immune Thrombocytopenia (ITP)
LaunchedApproved & Commercialized
Key Facts
Indication
Chronic Immune Thrombocytopenia (ITP)
Phase
Launched
Status
Approved & Commercialized
Company
About Mochida Pharmaceutical
Mochida Pharmaceutical is a mission-driven company focused on contributing to human health through the creation of innovative pharmaceuticals. It has achieved a dominant position in the Japanese market with a diversified portfolio and a robust, fully integrated operational model. Its core strategy balances the steady cash flows from its consumer healthcare and diagnostic businesses with targeted R&D investments in novel prescription drugs, supplemented by strategic global partnerships to access new technologies and markets. With a market capitalization of $127.8 billion, it represents a cornerstone of stability and long-term value in the biopharmaceutical sector.
View full company profileTherapeutic Areas
Other Chronic Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fostamatinib (TAVALISSE) | Nippon Shinyaku | Approved |
| Doptelet (avatrombopag) | Swedish Orphan Biovitrum | Marketed / Phase 4 |
| TAVALISSE (fostamatinib) | Rigel Pharmaceuticals | Marketed |